In our search of the DGIdb database for hSCI-DRGs we found that SLC3A2 is targeted by IGN523—a humanized antibody against CD98 currently used in anti-tumor applications [84], but its role in disulfidptosis remains unvalidated. Here, SLC3A2 is linked to neoplasm.